Nephros (NEPH) Net Income towards Common Stockholders (2010 - 2026)
Nephros' (NEPH) quarterly Net Income towards Common Stockholders came in at $29000.0 in Q1 2026, up 103.23% year-on-year from $14269.8 in Q1 2025, and down 53.23% quarter-over-quarter from $62000.0 in Q4 2025.
Nephros (NEPH) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Nephros' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at $29000.0 for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 103.23% year-over-year to $29000.0 in Q1 2026; TTM through Mar 2026 was $665000.0, a 203.74% increase from a year earlier, with the FY2025 full-year figure at $1.2 million, up 1513.51% from the prior year.
- Net Income towards Common Stockholders retreated to $29000.0 in Q1 2026 per NEPH's latest filing, from $62000.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $364000.0 in Q4 2024 and bottomed at -$3.2 million in Q3 2022.
- The 5-year median for Net Income towards Common Stockholders is -$289000.0 (2024), against an average of -$537705.9.
- Across the five-year window, Net Income towards Common Stockholders jumped 200.55% in 2024 and slumped 332.21% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$918000.0 in 2022, then climbed by 28.76% to -$654000.0 in 2023, then jumped by 155.66% to $364000.0 in 2024, then slumped by 82.97% to $62000.0 in 2025, then plunged by 53.23% to $29000.0 in 2026.
- Per Business Quant, the three latest NEPH Net Income towards Common Stockholders figures stand at $29000.0 (Q1 2026), $62000.0 (Q4 2025), and $337000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn | 22.13 Bn |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn | -274.00 Mn |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn | 239.00 Mn |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn | 398.73 Mn |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn | 147.90 Mn |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn | -77.90 Mn |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn | 13.00 Mn |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn | 112.77 Mn |
| 10 | Nephros | 40.88 Mn | 36.86 Mn | 2.99 Mn | 29,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29,000.00 |
| Dec 31, 2025 | 62,000.00 |
| Sep 30, 2025 | 337,000.00 |
| Jun 30, 2025 | 237,000.00 |
| Mar 31, 2025 | -899,000.00 |
| Dec 31, 2024 | 364,000.00 |
| Sep 30, 2024 | 183,000.00 |
| Jun 30, 2024 | -289,000.00 |
| Mar 31, 2024 | -208,000.00 |
| Dec 31, 2023 | -654,000.00 |
| Sep 30, 2023 | -182,000.00 |
| Jun 30, 2023 | -433,000.00 |
| Mar 31, 2023 | -306,000.00 |
| Dec 31, 2022 | -918,000.00 |
| Sep 30, 2022 | -3.23 Mn |
| Jun 30, 2022 | -1.20 Mn |
| Mar 31, 2022 | -2.03 Mn |
| Dec 31, 2021 | -1.10 Mn |
| Sep 30, 2021 | -1.22 Mn |
| Jun 30, 2021 | -1.19 Mn |